Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality

VV. McLaughlin, MM. Hoeper, RN. Channick, KM. Chin, M. Delcroix, S. Gaine, HA. Ghofrani, P. Jansa, IM. Lang, S. Mehta, T. Pulido, BKS. Sastry, G. Simonneau, O. Sitbon, R. Souza, A. Torbicki, VF. Tapson, L. Perchenet, R. Preiss, P. Verweij, LJ....

. 2018 ; 71 (7) : 752-763. [pub] 20180220

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035393

BACKGROUND: Registry data suggest that disease progression in pulmonary arterial hypertension (PAH) is indicative of poor prognosis. However, the prognostic relevance of PAH-related morbidity has not been formally evaluated in randomized controlled trials. OBJECTIVES: The purpose of these analyses was to assess the impact of morbidity events on the risk of subsequent mortality using the landmark method and data from the SERAPHIN and GRIPHON studies. METHODS: For each study, the risk of all-cause death up to the end of the study was assessed from the landmark time point (months 3, 6, and 12) according to whether a patient had experienced a primary endpoint morbidity event before the landmark. Each analysis was conducted using data from all patients who were available for survival follow-up at the landmark. RESULTS: In the SERAPHIN study, on the basis of the 3-month landmark time point, patients who experienced a morbidity event before month 3 had an increased risk of death compared with patients who did not (hazard ratio [HR]: 3.39; 95% confidence interval [CI]: 1.94 to 5.92). In the GRIPHON study, on the basis of the 3-month landmark time point, there was also an increased risk with a HR of 4.48; (95% CI: 2.98 to 6.73). Analyses based on 6-month and 12-month landmarks also showed increased risk in patients who experienced morbidity events, albeit with a reduced HR. CONCLUSIONS: These results demonstrate the prognostic relevance of PAH-related morbidity as defined in the SERAPHIN and GRIPHON studies, highlighting the importance of preventing disease progression in patients with PAH and supporting the clinical relevance of SERAPHIN and GRIPHON morbidity events. (Study of Macitentan [ACT-064992] on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension [SERAPHIN]; NCT00660179; Selexipag [ACT-293987] in Pulmonary Arterial Hypertension [GRIPHON]; NCT01106014).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035393
003      
CZ-PrNML
005      
20191010125052.0
007      
ta
008      
191007s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jacc.2017.12.010 $2 doi
035    __
$a (PubMed)29447737
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a McLaughlin, Vallerie V $u Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan. Electronic address: vmclaugh@med.umich.edu.
245    10
$a Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality / $c VV. McLaughlin, MM. Hoeper, RN. Channick, KM. Chin, M. Delcroix, S. Gaine, HA. Ghofrani, P. Jansa, IM. Lang, S. Mehta, T. Pulido, BKS. Sastry, G. Simonneau, O. Sitbon, R. Souza, A. Torbicki, VF. Tapson, L. Perchenet, R. Preiss, P. Verweij, LJ. Rubin, N. Galiè,
520    9_
$a BACKGROUND: Registry data suggest that disease progression in pulmonary arterial hypertension (PAH) is indicative of poor prognosis. However, the prognostic relevance of PAH-related morbidity has not been formally evaluated in randomized controlled trials. OBJECTIVES: The purpose of these analyses was to assess the impact of morbidity events on the risk of subsequent mortality using the landmark method and data from the SERAPHIN and GRIPHON studies. METHODS: For each study, the risk of all-cause death up to the end of the study was assessed from the landmark time point (months 3, 6, and 12) according to whether a patient had experienced a primary endpoint morbidity event before the landmark. Each analysis was conducted using data from all patients who were available for survival follow-up at the landmark. RESULTS: In the SERAPHIN study, on the basis of the 3-month landmark time point, patients who experienced a morbidity event before month 3 had an increased risk of death compared with patients who did not (hazard ratio [HR]: 3.39; 95% confidence interval [CI]: 1.94 to 5.92). In the GRIPHON study, on the basis of the 3-month landmark time point, there was also an increased risk with a HR of 4.48; (95% CI: 2.98 to 6.73). Analyses based on 6-month and 12-month landmarks also showed increased risk in patients who experienced morbidity events, albeit with a reduced HR. CONCLUSIONS: These results demonstrate the prognostic relevance of PAH-related morbidity as defined in the SERAPHIN and GRIPHON studies, highlighting the importance of preventing disease progression in patients with PAH and supporting the clinical relevance of SERAPHIN and GRIPHON morbidity events. (Study of Macitentan [ACT-064992] on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension [SERAPHIN]; NCT00660179; Selexipag [ACT-293987] in Pulmonary Arterial Hypertension [GRIPHON]; NCT01106014).
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a plicní hypertenze $x diagnóza $x mortalita $x patofyziologie $7 D006976
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a morbidita $7 D009017
650    _2
$a mortalita $x trendy $7 D009026
650    _2
$a prognóza $7 D011379
650    _2
$a míra přežití $x trendy $7 D015996
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hoeper, Marius M $u Department of Respiratory Medicine, Hannover Medical School and German Centre for Lung Research, Hannover, Germany.
700    1_
$a Channick, Richard N $u Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
700    1_
$a Chin, Kelly M $u University of Texas Southwestern, Dallas, Texas.
700    1_
$a Delcroix, Marion $u University Hospitals Leuven, Leuven, Belgium.
700    1_
$a Gaine, Sean $u National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland.
700    1_
$a Ghofrani, Hossein-Ardeschir $u University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany; Department of Medicine, Imperial College London, London, United Kingdom.
700    1_
$a Jansa, Pavel $u Charles University, Prague, Czech Republic.
700    1_
$a Lang, Irene M $u Medical University of Vienna, Department of Internal Medicine II, Division of Cardiology, Allgemeines Krankenhaus, Vienna, Austria.
700    1_
$a Mehta, Sanjay $u Respirology Division, London Health Sciences Centre, Western University, London, Ontario, Canada.
700    1_
$a Pulido, Tomás $u Cardiopulmonary Department, Ignacio Chávez National Heart Institute, Mexico City, Mexico.
700    1_
$a Sastry, B K S $u CARE Hospitals, Hyderabad, India.
700    1_
$a Simonneau, Gérald $u Hôpital de Bicêtre, Paris, France.
700    1_
$a Sitbon, Olivier $u Hôpital de Bicêtre, Paris, France.
700    1_
$a Souza, Rogério $u INCOR Heart Institute, University of São Paulo, São Paulo, Brazil.
700    1_
$a Torbicki, Adam $u Medical Centre for Postgraduate Education, CMKP European Health Centre, Otwock, Poland.
700    1_
$a Tapson, Victor F $u Cedars-Sinai Medical Center, Los Angeles, California.
700    1_
$a Perchenet, Loïc $u Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
700    1_
$a Preiss, Ralph $u Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
700    1_
$a Verweij, Pierre $u Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
700    1_
$a Rubin, Lewis J $u Division of Pulmonary and Critical Care Medicine, University of California, San Diego Medical School, La Jolla, California.
700    1_
$a Galiè, Nazzareno $u Istituto di Malattie dell'Apparato Cardiovascolare, Università di Bologna, Bologna, Italy.
773    0_
$w MED00002964 $t Journal of the American College of Cardiology $x 1558-3597 $g Roč. 71, č. 7 (2018), s. 752-763
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29447737 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191010125511 $b ABA008
999    __
$a ok $b bmc $g 1452053 $s 1073943
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 71 $c 7 $d 752-763 $e 20180220 $i 1558-3597 $m Journal of the American College of Cardiology $n J. Am. Coll. Cardiol. $x MED00002964
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Možnosti archivace